CHANGES IN FECAL FAT AND MICROBIOTA WITH 1 MONTH OF ELEXACATOR/TEZACAFTOR/IVACAFTOR: INITIAL FINDINGS FROM THE PROMISE STUDY

被引：0
|
作者：
Hoffman, L. [1 ,3 ]
Pope, C. [3 ]
Hayden, H. [3 ]
Rowe, S. [2 ]
Salipante, S. [3 ]
Nichols, D. P. [1 ]
机构：
[1] Seattle Childrens Hosp, Seattle, WA USA
[2] Univ Alabama Birmingham, Coll Arts & Sci, Birmingham, AL USA
[3] Univ Washington, Seattle, WA 98195 USA
来源：
PEDIATRIC PULMONOLOGY | 2020年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
218
引用
收藏
页码：S124 / S124
页数：1
相关论文
共 37 条
  • [21] ASSOCIATION OF LEAN BODY MASS AND FAT MASS WITH 1-YEAR MORTALITY IN PATIENTS WITH HEART FAILURE: FINDINGS FROM THE CHINA-PEACE PROSPECTIVE HEART FAILURE STUDY
    Ge, Yilan
    Zhang, Lihua
    Gao, Yan
    Wang, Bin
    Li, Jing
    Zheng, Xin
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 547 - 547
  • [22] Addition of Obinutuzumab to Ibrutinib Enhances Depletion of CLL Cells in the Peripheral Blood and Bone Marrow after 1 Month of Combination Therapy: Initial Results from the Bloodwise TAP Iciclle Extension Study
    Rawstron, Andy C.
    Munir, Talha
    Munoz-Vicente, Samuel
    Brock, Kristian
    Yates, Francesca J.
    Bishop, Rebecca
    Dalal, Surita
    de Tute, Ruth Mary
    Bloor, Adrian
    Sheehy, Oonagh M.
    Pettitt, Andrew R.
    Fox, Christopher P.
    Fegan, Christopher
    Devereux, Stephen
    Macdonald, Donald
    Hillmen, Peter
    BLOOD, 2016, 128 (22)
  • [23] CHANGES IN QUALITY OF LIFE AND BACK PAIN IN WOMEN WITH OSTEOPOROSIS TREATED WITH RHPTH(1-34) (TERIPARATIDE): 36 MONTH RESULTS FROM THE EUROPEAN FORSTEO OBSERVATIONAL STUDY (EFOS)
    Fahrleitner-Pammer, A.
    Ljunggren, O.
    Langdahl, B.
    Walsh, B.
    Barker, C.
    Lems, W.
    Karras, D.
    Rajzbaum, G.
    Jakob, F.
    Barrett, A.
    Marin, F.
    OSTEOPOROSIS INTERNATIONAL, 2010, 21 : 156 - 157
  • [24] Changes in self-reported and parent-reported health-related quality of life in overweight children and adolescents participating in an outpatient training: findings from a 12-month follow-up study
    Finne, Emily
    Reinehr, Thomas
    Schaefer, Anke
    Winkel, Katrin
    Kolip, Petra
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2013, 11
  • [25] Changes in self-reported and parent-reported health-related quality of life in overweight children and adolescents participating in an outpatient training: findings from a 12-month follow-up study
    Emily Finne
    Thomas Reinehr
    Anke Schaefer
    Katrin Winkel
    Petra Kolip
    Health and Quality of Life Outcomes, 11
  • [26] Initial findings from a first-in-human, multicenter, open-label study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies
    Ullenhag, Gustav J.
    Carneiro, Ana
    Smith, Karin Enell
    Schultz, Lena
    Ambarkhane, Sumeet Vijay
    Landstrom, Tova
    Yachnin, Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] Safety findings from a 12-month phase III study (TRANSFORMS) comparing oral fingolimod (FTY720) and intramuscular interferon β-1a for relapsing-remitting multiple sclerosis
    Kappos, L.
    Cohen, J.
    Pelletier, J.
    Barkhof, F.
    Comi, G.
    Hartung, H. P.
    Montalban, X.
    Khatri, B.
    Jin, J.
    Stites, T.
    Wu, S.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S245 - S246
  • [28] Patient-derived xenografts (PDXs) generated from hormone receptor-positive breast cancer (BC) before and after cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) treatment: Initial findings from the PROMISE study
    Yu, Jia
    Suman, Vera J.
    He, Jun
    Sinnwell, Jason P.
    Moyer, Ann M.
    Qin, Bo
    Gu, Yayun
    Zhang, Huan
    Carter, Jodi M.
    Kalari, Krishna R.
    McMenomy, Brendan P.
    Liu, Minetta C.
    Haddad, Tufia C.
    Ruddy, Kathryn J.
    Couch, Fergus J.
    Moreno-Aspitia, Alvaro
    Northfelt, Donald W.
    Weinshilboum, Richard
    O'Sullivan, Ciara
    Goetz, Matthew P.
    Wang, Liewei
    CANCER RESEARCH, 2022, 82 (04)
  • [29] Addition of obinutuzumab to ibrutinib enhances depletion of CLL cells in the peripheral blood and bone marrow after 1 month & 6 months of combination therapy: initial results from the bloodwise TAP IcICLLe extension study
    Rawstron, Andy
    Munir, Talha
    Munoz-Vicente, Samuel
    Brock, Kristian
    Yates, Francesca
    Bishop, Rebecca
    Dalal, Surita
    de Tute, Ruth
    Bloor, Adrian
    Sheehy, Oonagh
    Pettitt, Andrew
    Fox, Christopher
    Fegan, Christopher
    Devereux, Stephen
    MacDonald, Donald
    Hillmen, Peter
    LEUKEMIA & LYMPHOMA, 2017, 58 : 233 - 234
  • [30] Initial findings from an ongoing first-in-human phase 1 study of the CBP/p300 inhibitor FT-7051 in men with metastatic castration-resistant prostate cancer
    Armstrong, Andrew J.
    Gordon, Michael S.
    Reimers, Melissa A.
    Hussain, Arif
    Patel, Vaibhav G.
    Lam, Elaine T.
    Sedkov, Alex
    Potter, Von
    Shore, Neal
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
1234